You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK):將於SITC 2022年會公佈兩項科學壁報的最新業務進展

格隆匯10月14日丨創勝集團-B(06628.HK)發佈公吿,其將於2022年11月8日至12日於美國波士頓舉辦的第37屆癌症免疫治療學會(SITC)年會期間,以壁報形式公佈兩項科學壁報。其中一項與TST001 (Osemitamab)有關,研究了Claudin18.2和PD-L1在中國胃腺癌和食管胃結合部腺癌中的表達,另一項則為TST005(PD-L1/TGF-β雙重功能抗體)的臨牀研究介紹(Trial in Progress)摘要。

根據披露,癌症免疫治療學會(SITC)是世界領先的致力於推進癌症免疫治療科學與應用,以改善癌症患者的臨牀預後的成員驅動型組織。SITC的願景是通過促進科學交流和合作的教育專案,讓世界各地癌症患者被“治癒”在某一天能夠成為現實。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account